dalteparin sodium
Fragmin
Pharmaceutical company: Pfizer
NEW INDICATION & DOSAGE
Symptomatic venous thromboembolism in children
Children from birth (gestational age at least 35 weeks) to younger than 2 years: 150 international units/kg subcut b.i.d. for three doses; then assess anti-Xa level.
Adjust-a-dose: Adjust dosage in increments of 25 international units/kg to achieve target anti-Xa level between 0.5 and 1 international unit/mL. If the platelet count is 50,000 to 100,000/mm3, reduce dosage by 50% until platelet count exceeds 100,000/mm3. If the platelet count is less than 50,000/mm3, stop the drug until the platelet count exceeds 50,000/mm3.
Released: December 2024
Nursing Drug Handbook
© 2024 Wolters Kluwer
dupilumab
Dupixent
Pharmaceutical company: Sanofi and Regeneron Pharmaceuticals
NEW INDICATION & DOSAGE
Add-on maintenance treatment for inadequately controlled COPD and an eosinophilic phenotype
Adults: 300 mg subcut every other week.
Released: December 2024
Nursing Drug Handbook
© 2024 Wolters Kluwer
nivolumab
Opdivo
Pharmaceutical company: Bristol Myers Squibb
NEW INDICATION & DOSAGE
Neoadjuvant treatment of resectable non–small-cell lung cancer (tumors at least 4 cm or node-positive) without known epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements, in combination with platinum-doublet chemotherapy; followed by single-agent nivolumab as adjuvant treatment
Adults: 360-mg IV infusion with platinum-doublet chemotherapy on the same day every 3 weeks for up to 4 cycles or until disease progression or unacceptable toxicity occurs; then as a single-agent, 480 mg every 4 weeks after surgery for up to 13 cycles or until disease recurrence or unacceptable toxicity occurs.
Released: December 2024
Nursing Drug Handbook
© 2024 Wolters Kluwer
onabotulinumtoxinA
Botox Cosmetic
Pharmaceutical company: Allergan Aesthetics/AbbVie
INDICATION & DOSAGE
Temporary improvement in the appearance of moderate to severe platysma bands associated with platysma muscle activity
Adults: 2 units (0.05 mL) IM into each of four sites in the upper segment of the platysma muscles below the jawline on each side; and 1 unit (0.025 mL) into five sites on each vertical neck band per side (1 to 2 bands per side). Depending on platysma band severity, total dose may be 26 units (1 band per side), 31 units (1 band one side, 2 bands other side), or 36 units (2 bands each side). Administer no more frequently than every 3 months.
Released: December 2024
Nursing Drug Handbook
© 2024 Wolters Kluwer
osimertinib
Tagrisso
Pharmaceutical company: AstraZeneca
NEW INDICATION & DOSAGE
Locally advanced, unresectable (stage III) non–small-cell lung cancer in patients whose disease hasn't progressed during or after concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations
Adults: 80 mg PO once daily until disease progression or unacceptable toxicity occurs.
Released: December 2024
Nursing Drug Handbook
© 2024 Wolters Kluwer